Edition:
United Kingdom

Biomarin Receives Standard Approval For Palynziq For Treatment Of Rare Genetic Disease


Thursday, 24 May 2018 

May 24 (Reuters) - Biomarin Pharmaceutical Inc ::BIOMARIN RECEIVES STANDARD APPROVAL FOR PALYNZIQ™ (PEGVALIASE-PQPZ) INJECTION FOR TREATMENT OF ADULTS WITH PHENYLKETONURIA (PKU), A RARE GENETIC DISEASE.BIOMARIN PHARMACEUTICAL INC - PALYNZIQ IS EXPECTED TO BE AVAILABLE IN UNITED STATES BY END OF JUNE.